Research programme: TLR9 antagonists - Pfizer

Drug Profile

Research programme: TLR9 antagonists - Pfizer

Alternative Names: TLR9 antagonists - Pfizer

Latest Information Update: 13 Aug 2009

Price : $50

At a glance

  • Originator Coley Pharmaceutical Group
  • Class Small molecules
  • Mechanism of Action Toll-like receptor 9 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Autoimmune disorders

Most Recent Events

  • 28 Oct 2004 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top